In an effort to bolster domestic medicine production and decrease reliance on imports, Indonesia and Russia are engaging in discussions to facilitate pharmaceutical technology transfers. The collaboration aims to enhance regulatory oversight of medicines and food products, as officials from both nations met to explore potential avenues for cooperation.
The talks, conducted between Indonesia’s Food and Drug Authority (BPOM) and Russia’s Ministry of Industry and Trade, focused on several key areas, including pharmaceutical manufacturing, quality inspections, and the implementation of digital technologies to ensure product safety and traceability. Indonesia emphasized the need to expand local production of diabetes treatments, such as insulin and GLP-1 medicines, to boost access to essential healthcare products.
Potential cooperation extends beyond diabetes treatments, as discussions also covered cancer therapies, monoclonal antibodies, antiviral medications, and advanced biotechnology products. Russian pharmaceutical companies have shown interest in transferring technology and possibly setting up manufacturing facilities in Indonesia, specifically targeting insulin, oncology medicines, and biotechnology products. Additionally, several Russian firms have already submitted product registration documents to BPOM.
Existing collaborations were reviewed, including those related to Good Manufacturing Practice (GMP) inspections, technical training, and sharing of information. The two countries discussed finalizing a memorandum of understanding to establish a framework for deeper collaboration. Russia proposed the mutual recognition of GMP certificates, which could simplify regulatory procedures and facilitate market access for pharmaceuticals in both countries, though this proposal requires further discussion to ensure regulatory compatibility.
To enhance Indonesia’s inspection capabilities, Russia offered technical training, which includes innovative approaches such as virtual reality-based simulations to prepare inspectors for pharmaceutical manufacturing assessments. The conversation also included discussions on digital regulatory systems and supply-chain monitoring, with both parties expressing interest in continuing negotiations and expanding cooperation through future meetings and facility visits.